Living ahead of the curve with IMBRUVICA® + venetoclax[1][2][3]
IMBRUVICA® + venetoclax combination therapy is the only all-oral, chemo-free, fixed-duration, first-line therapy indicated for the treatment of chronic lymphocytic leukaemia (CLL).[1][2][3]
Explore IMBRUVICA® and CLL in depth
Find out more about the IMBRUVICA® + venetoclax combination therapy
Synergistic MoA
Strength through synergy: Two powerful targeted therapies in first-line CLL built for one outcome – treatment-free remission[1][3][4][5][6]
Efficacy
A synergistic MoA that demonstrates disease clearance across multiple compartments, provides deep, durable responses, and prolongs PFS[1][2][4][5][6]*
Safety
Starting with a 3-cycle lead-in, IMBRUVICA® reduces TLS risk in 94% of high-risk patients and the combination demonstrated no new safety signals[7]†‡
Fixed-duration dosing
The only all-oral, chemo-free, fixed-duration therapy[1][2]
Explore IMBRUVICA® monotherapy in CLL
Explore IMBRUVICA® resources
CLL=chronic lymphocytic leukaemia; MoA=mechanism of action; PFS=progression free survival; TLS=tumour lysis syndrome.
*Prolongs PFS vs chlorambucil + obinutuzumab.[1][5]
†In the CAPTIVATE study, 94% of patients (32/34) moved from a high- to medium- or low-risk TLS category.[7]
‡No new safety signals when comparing adverse events on IMBRUVICA® + venetoclax combination therapy versus either as monotherapy in CLL.[1][2][3][7][8]
IMBRUVICA is indicated for treatment of adult patients: as a single agent for relapsed/refractory mantle cell lymphoma (MCL); as a single agent or in combination with rituximab or obinutuzumab or venetoclax for previously untreated chronic lymphocytic leukaemia (CLL); as a single agent or in combination with bendamustine and rituximab (BR) in CLL after at least one prior therapy; as a single agent for Waldenström’s macroglobulinaemia (WM) after at least one prior therapy, or in first line treatment for patients unsuitable for chemo‑immunotherapy; in combination with rituximab for WM.[3]
| Adverse events should be reported. Reporting an adverse event will help J&J monitor the safety of all our healthcare products for the benefit of patients and consumers. It is important to report adverse events, even if it is a known adverse event, as this provides valuable information for monitoring product safety, allowing J&J to provide up-to-date information in the Summary of Product Characteristics and product information leaflets. For Adverse Events or safety related issues on J&J products, please approach the mailbox PVNEMA@ITS.JNJ.COM or Tel: +961 1 518769/ +961 1 518775 |
